文献速递主动脉疾病内脏/肾动脉与血管畸形

既往开放腹主动脉修复术后行开窗/分支胸腹主动脉腔内修复术的早中期结果

Fenestrated and Branched Thoraco-abdominal Endografting after Previous Open Abdominal Aortic Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-08-24

本研究回顾性分析了两家欧洲血管外科中心2006至2017年前瞻性收集的108例既往开放腹主动脉修复术后发生近端吻合口周围动脉瘤或自体主动脉瘤样变的患者,均接受开窗/分支腔内修复术(FB-EVAR)。总体技术成功率为93%,30天死亡率为4%,住院死亡率为5.5%,随访期间靶内脏血管通畅率1、3、5年分别为93%、91%、91%。结论认为FB-EVAR安全有效,尤其适用于高危患者。

要点

  • FB-EVAR治疗既往开放腹主动脉修复术后近端动脉瘤样变技术成功率93%,30天死亡率4%。
  • 术后脊髓缺血发生率为6.5%,永久性脊髓缺血为3.7%,在Crawford I-III型及同时使用开窗和分支的移植物中更常见。
  • 随访1、3、5年生存率分别为82%、64%、54%,靶内脏血管通畅率分别为93%、91%、91%。

核心结论

  • FB-EVAR治疗既往开放腹主动脉修复术后近端主动脉瘤样变安全有效,若长期随访证实,应视为重要治疗选择,尤其在高危患者中。

研究设计与样本

  • 多中心回顾性分析,前瞻性收集2006至2017年两家欧洲血管外科中心108例既往开放腹主动脉修复术后接受FB-EVAR的患者资料。
  • 108例患者中男性占94%,平均年龄71±4岁,ASA 3级占74%、4级占26%,距前次开放修复平均10±2年。

主要发现

  • 总体技术成功率为93%,技术失败包括5例靶内脏血管丢失(腹腔干1例、肾动脉4例)和3例24小时内死亡。
  • 心脏、肺和肾脏并发症(肾小球滤过率较基线下降≥30%)发生率分别为9%、10%和20%,肠缺血3例(2.8%)。
  • 平均随访38±18个月,1、3、5年生存率分别为82%、64%、54%,靶内脏血管通畅率分别为93%、91%、91%,免于再干预率分别为89%、77%、74%。

临床怎么用

  • 对于既往开放腹主动脉修复术后出现近端吻合口周围动脉瘤或自体主动脉瘤样变的患者,FB-EVAR可作为安全有效的治疗选择,尤其适用于高危患者。
  • 术前慢性肾功能衰竭、术后心脏并发症、脊髓缺血和肠缺血与随访期生存显著相关,围术期应加强相关器官保护。

局限性

  • 本研究为回顾性分析,样本来自两家欧洲中心,结果需在更长期随访中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Proximal para-anastomotic aneurysms, or aneurysmal degeneration of the native aorta above a previous open abdominal aortic repair (Pr-AAAs), are challenging scenarios. The aim of this study was to report the early and mid term outcomes of endovascular repair of Pr-AAAs by fenestrated and branched endovascular aneurysm repair (FB-EVAR). METHODS: From 2006 to 2017, pre-operative, intra-operative, and post-operative data from patients undergoing FB-EVAR for Pr-AAAs at two European vascular surgery units were prospectively collected and retrospectively analysed. Early results were considered in terms of technical success (target visceral vessel cannulation and stenting, absence of type I - III endoleak, iliac limb occlusion and 24 h mortality); spinal cord ischaemia (SCI) and 30 day and in hospital mortality. Survival, target visceral vessel (TVV) patency, and freedom from re-interventions were also considered at the mid term follow up. RESULTS: Five hundred and forty-four patients underwent FB-EVAR to treat juxta/pararenal or thoraco-abdominal aneurysms. Of these patients, 108 (19.8%) cases were Pr-AAAs (94% male; mean ± standard deviation [SD] age 71 ± 4 years; American Society of Anesthesiologists' grade 3-4 in 74% and 26%, respectively). The previous open aortic repair (OR) was performed 10 ± 2 years before FB-EVAR. It was a tubular aorto-aortic repair in 63 (58.3%) cases, a bifurcated aortobi-iliac repair in 37 (34.2%) cases, and an aortobifemoral bypass repair in eight (7.4%) cases. A previous thoracic endovascular aneurysm repair (TEVAR) had been performed in seven patients (6.5%). The aortic lesion at the time of FB-EVAR was, according to the Crawford classification, a type I - III in 69 (63.9%) or a type IV 39 (36.1%) thoraco-abdominal aneurysm. The mean ± SD aneurysm diameter was 64 ± 6 mm. Overall, 390 TVVs (3.6 ± 1 TVV/case) were revascularised by an endograft with fenestrations (n = 63 [58.3%]), with branches (n = 26 [24.1%]), or with both fenestrations and branches (n = 19 [17.6%]). Tubular, trimodular, or aorto-uni-iliac implants were planned in 68 (63.0%), 38 (35.2%), and two (1.8%) patients, respectively. Proximal TEVAR, carotid-subclavian bypass, and iliac branch devices were planned as adjunctive procedures in 41 (38.0%), five (4.6%), and three (2.8%) cases, respectively. Overall technical success was 93%, with technical failures including five TVV losses (coeliac trunk, n = 1; renal arteries, n = 4) and three deaths within 24 h. Post-operative SCI occurred in seven patients (6.5%), four of which (3.7%) were permanent. SCI was more frequent in category I - III TAAAs (p = .042) and in endografts incorporating both fenestrations and branches (p = .023). Cardiac, pulmonary, and renal complications (reduction in glomerular filtration rate of ≥30% compared with baseline) occurred in 9%, 10%, and 20%, respectively. Bowel ischaemia was seen in three (2.8%) patients. Thirty day mortality was 4% and was associated with pre-operative chronic renal failure (p = .034), post-operative cardiac morbidity (p = .041), and bowel ischaemia (p = .003). Overall in hospital mortality was 5.5% (n = 6). Mean ± SD follow up was 38 ± 18 months. Survival was 82%, 64%, and 54% at one, three, and five years, respectively, and target visceral vessel patency was 93%, 91%, and 91%, respectively. Permanent haemodialysis was needed in four patients (3.7%). There was no late aneurysm related mortality. Survival during follow up was statistically significantly affected by pre-operative chronic renal failure (p = .022), post-operative cardiac morbidity (p = .042), SCI (p = .044), and bowel ischaemia (p = .003). Freedom from re-intervention at one, three, and five years was 89%, 77%, and 74%, respectively. CONCLUSION: Endovascular treatment of aneurysmal aortic degeneration above a previous open abdominal repair with FB-EVAR is safe and effective. If those promising results are confirmed at later follow up, FB-EVAR should be considered a prominent therapeutic option, especially in high risk patients.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Gallitto E, Sobocinski J, Mascoli C, et al. Fenestrated and Branched Thoraco-abdominal Endografting after Previous Open Abdominal Aortic Repair. Eur J Vasc Endovasc Surg. 2020. PMID: 32855033. doi:10.1016/j.ejvs.2020.07.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。